Companies Novavax Inc
Novavax (NVAX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Novavax Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers63rd pct.Of 20 peer CEOs
CEO pay, last three years
- $7,301,009FY2023
- $5,087,461FY2024
- $8,856,015FY2025
CEO total pay was $8,856,015 in fiscal 2025, up from $5,087,461 in fiscal 2024.
FY2025: salary $792,917 · bonus $0 · stock awards $3,545,435 · option awards $3,763,292
Executives and directors
James Kelly · CFOJohn Jacobs · CEOJohn Trizzino · PresidentMark Casey · General CounselRuxandra Draghia-Akli · ExecutiveElaine O'Hara · EVP, Chief Strategy OfficerCharles W. Newton · Independent DirectorDavid Mott · Chair of the BoardGregg H. Alton, J.D · Independent DirectorJames F. Young, Ph.D · Former director (through FY2025)John W. Shiver, Ph.D · Independent DirectorMargaret G. McGlynn, R. Ph · Independent DirectorRachel K. King · Independent DirectorRichard H. Douglas, Ph.D · Independent DirectorRichard J. Rodgers · Independent Director
Frequently asked questions
Who was the highest-paid executive at Novavax Inc in fiscal 2025?
As disclosed, John Jacobs (President and CEO) was the highest-paid executive at Novavax Inc in fiscal 2025, with total compensation of $8,856,015.
How does Novavax Inc's chief executive pay compare to its disclosed peer group?
As disclosed, John Jacobs's total compensation ranked at the 63rd percentile of Novavax Inc's disclosed peer group.
What is Novavax Inc's CEO-to-median employee pay ratio?
As disclosed, Novavax Inc's CEO-to-median employee pay ratio was 52:1.
How did shareholders vote on Novavax Inc's executive compensation?
As disclosed, 50.65% of shareholders supported Novavax Inc's executive compensation in the latest say-on-pay vote.
How much does Novavax Inc spend in total on board compensation for fiscal 2025?
As disclosed, Novavax Inc reported total board compensation of $1,793,767 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Jacobs | $792,917 | $0 | $3,545,435 | $3,763,292 | $640,331 | $0 | $114,040 | $8,856,015 |
| President and CEO | ||||||||
| Elaine O'Hara | 561,080 | 0 | 1,330,030 | 1,411,235 | 288,143 | 0 | 97,788 | 3,688,276 |
| EVP, Chief Strategy Officer | ||||||||
| James Kelly | 572,886 | 0 | 1,019,165 | 1,082,782 | 297,362 | 0 | 14,033 | 2,986,228 |
| EVP, Chief Financial Officer and Treasurer | ||||||||
| Mark Casey | 577,831 | 0 | 885,375 | 940,823 | 289,660 | 0 | 116,764 | 2,810,453 |
| EVP, Chief Legal Officer and Corporate Secretary | ||||||||
| Ruxandra Draghia-Akli | 600,000 | 0 | 629,600 | 668,040 | 290,250 | 0 | 115,490 | 2,303,380 |
| Former EVP, Head of Research & Development | ||||||||
| John Trizzino | 310,016 | 0 | 368,624 | 209,724 | 0 | 0 | 821,586 | 1,709,950 |
| Former President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Jacobs | $8,856,015 | $5,087,461 | $7,301,009 | ↑ +3,768,554 |
| Elaine O'Hara | 3,688,276 | 1,638,116 | — | ↑ +2,050,160 |
| James Kelly | 2,986,228 | 1,829,489 | 1,503,833 | ↑ +1,156,739 |
| Mark Casey | 2,810,453 | 1,062,334 | 1,534,587 | ↑ +1,748,119 |
| Ruxandra Draghia-Akli | 2,303,380 | — | — | — |
| John Trizzino | 1,709,950 | 1,633,417 | 1,877,883 | ↑ +76,533 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ruxandra Draghia-Akli | RSU | 2025-03-03 | — | — | 80,000 | — | $629,600 |
| Ruxandra Draghia-Akli | OPTION | 2025-03-03 | — | — | 120,000 | — | 668,040 |
| John Jacobs | RSU | 2025-03-03 | — | — | 450,500 | — | 3,545,435 |
| John Jacobs | OPTION | 2025-03-03 | — | — | 676,000 | — | 3,763,292 |
| James Kelly | OPTION | 2025-03-03 | — | — | 194,500 | — | 1,082,782 |
| Elaine O Hara | RSU | 2025-03-03 | — | — | 169,000 | — | 1,330,030 |
| Mark Casey | RSU | 2025-03-03 | — | — | 112,500 | — | 885,375 |
| James Kelly | RSU | 2025-03-03 | — | — | 129,500 | — | 1,019,165 |
| Mark Casey | OPTION | 2025-03-03 | — | — | 169,000 | — | 940,823 |
| Elaine O Hara | OPTION | 2025-03-03 | — | — | 253,500 | — | 1,411,235 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ruxandra Draghia-Akli | $629,600 | $0 | $668,040 | 0.0% |
| John Jacobs | 3,545,435 | 0 | 3,763,292 | 0.0% |
| James Kelly | 1,019,165 | 0 | 1,082,782 | 0.0% |
| Elaine O Hara | 1,330,030 | 0 | 1,411,235 | 0.0% |
| Mark Casey | 885,375 | 0 | 940,823 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Kelly | Option | 1,297 | 77.77 | — |
| John Trizzino | Option | 1,297 | 77.77 | — |
| Mark Casey | RSU | 8,000 | — | 53,760 |
| James Kelly | RSU | 12,223 | — | 82,139 |
| James Kelly | Option | 13,235 | 6.97 | — |
| Elaine O'Hara | RSU | 19,600 | — | 131,712 |
| Elaine O'Hara | Option | 21,219 | 6.86 | — |
| Ruxandra Draghia-Akli | RSU | 28,513 | — | 191,607 |
| John Trizzino | RSU | 28,890 | — | 194,141 |
| Mark Casey | RSU | 41,899 | — | 281,561 |
| John Trizzino | Option | 46,777 | 9.01 | — |
| Elaine O'Hara | Option | 72,348 | 5.57 | — |
| John Jacobs | Option | 78,732 | 11.92 | — |
| Elaine O'Hara | RSU | 80,000 | — | 537,600 |
| Ruxandra Draghia-Akli | RSU | 80,000 | — | 537,600 |
| John Jacobs | RSU | 83,197 | — | 559,084 |
| John Trizzino | RSU | 96,000 | — | 645,120 |
| Mark Casey | RSU | 112,500 | — | 756,000 |
| James Kelly | RSU | 117,333 | — | 788,478 |
| Ruxandra Draghia-Akli | Option | 120,000 | 7.87 | — |
| James Kelly | RSU | 129,500 | — | 870,240 |
| John Jacobs | RSU | 166,666 | — | 1,119,996 |
| Elaine O'Hara | RSU | 169,000 | — | 1,135,680 |
| Mark Casey | Option | 169,000 | 7.87 | — |
| James Kelly | Option | 194,500 | 7.87 | — |
| Elaine O'Hara | Option | 253,500 | 7.87 | — |
| John Jacobs | Option | 281,251 | 5.39 | — |
| John Jacobs | RSU | 450,500 | — | 3,027,360 |
| John Jacobs | Option | 676,000 | 7.87 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John W. Shiver, Ph.DIndependent · Compensation | $59,987 | $195,011 | $261,547 | — | — | $516,545 |
| Charles W. NewtonIndependent · Capital Allocation · Audit · Nominating & Corporate Governance · Independent · Newly elected | 45,982 | 190,495 | 255,472 | — | — | 491,949 |
| Margaret G. McGlynn, R. PhIndependent · Nominating & Corporate Governance · Independent · Research & Development | 119,187 | 121,021 | 162,070 | 0 | 0 | 402,278 |
| Richard J. RodgersIndependent · Compensation · Capital Allocation · Audit (Chair) · Independent | 92,358 | 121,021 | 162,070 | 0 | 0 | 375,449 |
| David MottIndependent · Board Chair · Compensation (Chair) · Capital Allocation · Independent · Research & Development | 82,500 | 121,021 | 162,070 | 0 | 0 | 365,591 |
| Richard H. Douglas, Ph.DIndependent · Audit | 81,371 | 121,021 | 162,070 | 0 | 0 | 364,462 |
| Gregg H. Alton, J.DIndependent · Capital Allocation · Audit · Nominating & Corporate Governance · Independent · Compensation | 72,000 | 121,021 | 162,070 | 0 | 0 | 355,091 |
| Rachel K. KingIndependent · Compensation · Nominating & Corporate Governance · Independent | 70,000 | 121,021 | 162,070 | 0 | 0 | 353,091 |
| James F. Young, Ph.DIndependent · Departed during FY | 58,750 | — | — | — | 0 | 58,750 |
| John C. JacobsEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $350,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,500 |
| Stock ownership guideline | ck equivalent in value to a multiple of the individual’s salary or, in the case of directors, their annual cash retainer, as follows: |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $682,135 |
| Equity awards (grant-date value) | $1,111,632 |
| All other compensation | $0 |
| Total cost of the board | $1,793,767 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Novavax as a peer
Companies that benchmark against NVAX
5 companies name NVAX as a compensation peer
- Arcturus Therapeutics Holdings Inc.ARCTFY2025
- DYNAVAX TECHNOLOGIES CORPDVAXFY2024
- ImmunityBio, Inc.IBRXFY2025
- Supernus, Inc.INDVFY2025
- UNITED THERAPEUTICS CorpUTHRFY2025
Each company listed discloses NVAX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NVAX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
RARE Ultragenyx Pharmaceutical Inc.NTLA Intellia Therapeutics, Inc.DNLI Denali Therapeutics Inc.EBS Emergent BioSolutions Inc.BCRX BioCryst Pharmaceuticals, Inc.PCRX Pacira BioSciences, Inc.BEAM Beam Therapeutics Inc.CRNX Crinetics Pharmaceuticals, Inc.ANIP ANI Pharmaceuticals, Inc.VIR Vir Biotechnology, Inc.SUPN Supernus Pharmaceuticals, Inc.DVAX Dynavax Technologies CorporationCORT Corcept Therapeutics IncorporatedALKS Alkermes plcACAD ACADIA Pharmaceuticals Inc.PCTX PTC Therapeutics, Inc.ARVN Arvinas, IncSANA Sana Biotechnology, Inc.AMPH Amphastar Pharmaceuticals, Inc.BCYC Bicycle
Peer reciprocity
The companies Novavax Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | $1,036,000 | $6,535,029 | $7,031,545 | $846,930 | $15,501,557 |
| 2 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 3 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 4 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 5 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 6 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 7 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 8 | Novavax Inc | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 9 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 10 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 11 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 12 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 13 | Vir Biotechnology, Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 14 | Arvinas, Inc | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 15 | Bicycle | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 16 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 17 | Emergent BioSolutions Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
| 18 | Intellia Therapeutics, Inc. | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 19 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 20 | Sana Biotechnology, Inc. | 2025 | Steven Harr | 696,140 | 425,001 | 1,327,500 | 450,369 | 2,903,010 |
| — | PTC Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Novavax Inc | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Arvinas, Inc | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Bicycle | 97% | not disclosed | not disclosed | not disclosed |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Emergent BioSolutions Inc. | 107% | Options 50 · PSU 50 | No | WTW |
| Intellia Therapeutics, Inc. | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Sana Biotechnology, Inc. | 107.5% | not disclosed | not disclosed | Aon plc (Human Capital Solutions practice) |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vir Biotechnology, Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 35,779,461 | 34,858,658 | 737,897 | 50.65% | Passed |
| 2025 | 2025-06-20 | 41,390,651 | 15,830,308 | 530,262 | 72.33% | Passed |
| 2024 | 2024-06-13 | 24,187,672 | 8,695,357 | 11,007,350 | 73.56% | Passed |
| 2023 | 2023-07-11 | 15,695,578 | 3,030,052 | 538,435 | 83.82% | Passed |
| 2022 | 2022-06-16 | 19,618,798 | 6,574,169 | 243,539 | 74.9% | Passed |
| 2021 | 2021-06-17 | 31,917,668 | 8,631,639 | 340,263 | 78.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-18 | 50.65%a |
| 2025 | 2025-06-20 | 72.33%b |
| 2024 | 2024-06-13 | 73.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as shares voting on this matter and accordingly will have no effect on the approval of this Proposal 3.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 52 : 1 |
|---|---|
| CEO total compensation | $8,856,015 |
| Median employee compensation | $169,449 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John W. Shiver | Director | 2026-06-18 | A | 21,270 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Shiver | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (82 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Jacobs. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 8,856,015. View filing ↗
- Section 01, Elaine O'Hara. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 3,688,276. View filing ↗
- Section 01, James Kelly. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 2,986,228. View filing ↗
- Section 01, Mark Casey. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 2,810,453. View filing ↗
- Section 01, Ruxandra Draghia-Akli. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 2,303,380. View filing ↗
- Section 01, John Trizzino. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 1,709,950. View filing ↗
- Section 03, Ruxandra Draghia-Akli RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Ruxandra Draghia-Akli OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Jacobs RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, John Jacobs OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Kelly OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Elaine O Hara RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Casey RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Kelly RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Casey OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Elaine O Hara OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-27. Section “CEO Pay Ratio”. As printed: 52 : 1. View filing ↗
- Section 08, John W. Shiver, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 516,545. View filing ↗
- Section 08, Charles W. Newton. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 491,949. View filing ↗
- Section 08, Margaret G. McGlynn, R. Ph. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 402,278. View filing ↗
- Section 08, Richard J. Rodgers. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 375,449. View filing ↗
- Section 08, David Mott. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 365,591. View filing ↗
- Section 08, Richard H. Douglas, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 364,462. View filing ↗
- Section 08, Gregg H. Alton, J.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 355,091. View filing ↗
- Section 08, Rachel K. King. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 353,091. View filing ↗
- Section 08, James F. Young, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 58,750. View filing ↗
- Section 08, John C. Jacobs. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, John W. Shiver 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret G. McGlynn 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Shiver 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg H. Alton 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg H. Alton 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret G. McGlynn 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachel K. King 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachel K. King 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Rodgers 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Rodgers 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret G. McGlynn 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret G. McGlynn 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachel K. King 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachel K. King 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Rodgers 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Rodgers 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg H. Alton 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg H. Alton 2026-06-20. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-23. Item 5.07 · say-on-pay result. As reported: 50.65% (votes for as printed: 35,779,461). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-24. Item 5.07 · say-on-pay result. As reported: 72.33% (votes for as printed: 41,390,651). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 73.56% (votes for as printed: 24,187,672). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 682,135 + equity 1,111,632 + all other 0 = 1,793,767, summed across the director compensation table rows.
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. View filing ↗
- BioCryst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. View filing ↗
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Crinetics Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- ANI Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Novavax Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Novavax Inc's own proxy. As printed: 8,856,015. View filing ↗
- Amphastar Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Dynavax Technologies Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. View filing ↗
- Alkermes plc, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. View filing ↗
- Vir Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. View filing ↗
- Arvinas, Inc, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc's own proxy. As printed: 6,534,127. View filing ↗
- Bicycle, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bicycle's own proxy. As printed: 6,341,473. View filing ↗
- Beam Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. View filing ↗
- Emergent BioSolutions Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. View filing ↗
- Intellia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Sana Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. View filing ↗
- Section 10a, Dynavax Technologies Corporation reciprocity. DEF 14A. Dynavax Technologies Corporation names Novavax Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗